6/22
01:06 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
6/14
08:13 am
mbrx
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial [Yahoo! Finance]
High
Report
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial [Yahoo! Finance]
6/14
08:00 am
mbrx
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
High
Report
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
6/13
04:00 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
6/12
09:00 am
mbrx
Moleculin to Present at the Virtual Investor Pitch Conference
Low
Report
Moleculin to Present at the Virtual Investor Pitch Conference
6/5
09:14 am
mbrx
Moleculin to Participate in the Virtual Investor Lunch Break Series [Yahoo! Finance]
Medium
Report
Moleculin to Participate in the Virtual Investor Lunch Break Series [Yahoo! Finance]
6/5
08:55 am
mbrx
Moleculin to Participate in the Virtual Investor Lunch Break Series
Medium
Report
Moleculin to Participate in the Virtual Investor Lunch Break Series
5/16
08:36 am
mbrx
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress [Yahoo! Finance]
Low
Report
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress [Yahoo! Finance]
5/16
08:32 am
mbrx
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Low
Report
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
5/16
07:17 am
mbrx
Moleculin begins NIH-funded Phase II glioblastoma treatment trial [Yahoo! Finance]
Low
Report
Moleculin begins NIH-funded Phase II glioblastoma treatment trial [Yahoo! Finance]
5/15
08:50 am
mbrx
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) [Yahoo! Finance]
Medium
Report
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) [Yahoo! Finance]
5/15
08:38 am
mbrx
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
Low
Report
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
5/15
03:16 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/13
07:34 am
mbrx
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/13
07:30 am
mbrx
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/9
08:35 am
mbrx
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin [Yahoo! Finance]
Medium
Report
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin [Yahoo! Finance]
5/9
08:30 am
mbrx
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Medium
Report
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
5/8
09:03 am
mbrx
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast [Yahoo! Finance]
Medium
Report
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast [Yahoo! Finance]
5/8
08:45 am
mbrx
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
Medium
Report
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
5/7
09:12 am
mbrx
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data [Yahoo! Finance]
Medium
Report
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data [Yahoo! Finance]
5/7
08:55 am
mbrx
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Medium
Report
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
5/7
03:37 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/2
09:00 am
mbrx
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Low
Report
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
5/1
08:54 am
mbrx
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin [Yahoo! Finance]
Low
Report
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin [Yahoo! Finance]
5/1
08:50 am
mbrx
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Low
Report
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin